- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03102437
Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System (FIX-HF-5CA)
November 21, 2021 updated by: Impulse Dynamics
FIX-HF-5CA: Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%
This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
The Continued Access study is a prospective, non-randomized, multi-center study designed to allow controlled access to the Optimizer Smart System until the PMA order has been issued by the FDA.
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- Chan Heart Rhythm Institute
-
Mesa, Arizona, United States, 85206
- Southwest Cardiology Associates
-
Phoenix, Arizona, United States, 85027
- Cardiovascular Consultants
-
Scottsdale, Arizona, United States, 85251
- Arizona Arrhythmia Consultants
-
Tucson, Arizona, United States, 85745
- Pima Heart
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
Lexington, Kentucky, United States, 40503
- Baptist Health Lexington
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Langhorne, Pennsylvania, United States, 19047
- St. Mary Research Institute
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Presbyterian Medical Center
-
Philadelphia, Pennsylvania, United States, 19047
- Jefferson Heart Institute
-
Sayre, Pennsylvania, United States, 18840
- Guthrie Medical Group at Robert Packer Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
Tyler, Texas, United States, 75701
- Christus Trinity Mother Frances Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who are 18 years of age or older
- Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography.
- Subjects who, in the opinion of the Investigator (based on the current guidelines for clinical practice), have been treated for heart failure for at least 90 days and are currently receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure.
- Subjects who are in New York Heart Association functional Class III and IV at the time of enrollment.
- Subjects who are willing and able to return for all follow-up visits.
Exclusion Criteria:
- Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.
- Subjects receiving any form of inotropic support within 30 days before enrollment, including subjects on continuous IV inotrope therapy.
- Subjects hospitalized for decompensated heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing.
- Subjects who have a clinically significant amount of ambient ectopy, defined as more than 8,900 PVCs per 24 hours on baseline Holter monitoring.
- Subjects having a PR interval greater than 375ms.
- Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.
- Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater.
- Subjects who have had a myocardial infarction within 90 days of enrollment.
- Subjects who have mechanical tricuspid valve.
- Subjects who have a Left Ventricular Assist Device or prior heart transplant.
- Subjects on dialysis.
- Subjects who are participating in another experimental protocol.
- Subjects who are unable to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Optimizer Smart System
All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
|
The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle.
Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observed Mortality Comparison to the Predicted Probability of Mortality
Time Frame: 2 years 6 months
|
The FIX-HF-5CA Study was unofficially intended to serve as the Post-Approval Study (PAS) with the intention of collecting 3 year observed mortality data and comparing that to the predicted probability of mortality derived from two validated heart failure models [MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and SHFM (Seattle Heart Failure Model)].
The objective was to show that the observed prevalence of mortality was not worse than the derived predicted probability of mortality.
Upon PMA and PMA Supplement approval of the device, however, FDA and the Sponsor stopped this 5CA study and a new PAS was initiated (NCT03970343).
No long-term mortality data or final analysis was collected for this study.
|
2 years 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Daniel Burkhoff, MD, PhD, Impulse Dynamics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2017
Primary Completion (Actual)
December 16, 2019
Study Completion (Actual)
December 16, 2019
Study Registration Dates
First Submitted
March 23, 2017
First Submitted That Met QC Criteria
March 30, 2017
First Posted (Actual)
April 5, 2017
Study Record Updates
Last Update Posted (Actual)
November 23, 2021
Last Update Submitted That Met QC Criteria
November 21, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP OPT2017-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Optimizer Smart System
-
Impulse DynamicsCompletedHeart Failure | Congestive Heart Failure | CHF | Chronic Heart DiseaseUnited States, Germany
-
Impulse DynamicsRecruiting
-
Impulse DynamicsCompletedHeart Failure, DiastolicSweden, Italy, Czechia, Spain, Australia, Germany, Poland, Portugal
-
National Medical Research Center for Cardiology...Ministry of Health, Russian FederationCompletedHeart Failure | Atrial Fibrillation | Left Ventricular Ejection FractionRussian Federation
-
Impulse DynamicsRecruitingHeart Failure | Heart Failure With Preserved Ejection Fraction | Diastolic Heart Failure | Heart Failure With Mid Range Ejection Fraction | Heart Failure With Moderately Reduced Ejection FractionUnited States
-
Impulse DynamicsCompletedHeart Failure, CongestiveUnited States
-
Heike Bischoff-FerrariRecruitingCardiovascular Diseases | Hypertension | Diabetes | Dementia | FrailtySwitzerland
-
Impulse DynamicsRecruitingHeart Failure | Arrhythmias, Cardiac | Ventricular Fibrillation | Ventricular Tachycardia | Implantable Defibrillator User | Heart Failure With Reduced Ejection Fraction | Ischemic Cardiomyopathy | Sudden Cardiac Arrest | Non-ischemic Cardiomyopathy | CCM TherapyUnited States
-
Impulse DynamicsCompletedNYHA Class III Heart Failure | NYHA Class IV Heart FailureUnited States, Germany, Czechia
-
National Rehabilitation Center, Seoul, KoreaUnknownUpper Extremity Rehabilitation Using SMART Glove System With Transcranial Direct Current StimulationStrokeKorea, Republic of